Epidermal growth factor cytoplasmic domain affects ErbB protein degradation by the lysosomal and ubiquitin-proteasome in human cancer cells

Neoplasia (United States)

Volumn 14, Issue 5, 2012, Pages 396-409

  Glogowska, Aleksandra ^a   Stetefeld, Jörg ^a   Weber, Ekkehard ^b   Ghavami, Saeid ^a   Hoang Vu, Cuong ^b   Klonisch, Thomas ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEASOME; SMALL INTERFERING RNA; UBIQUITIN THIOLESTERASE;

ARTICLE; CANCER INHIBITION; CELL FRACTIONATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; EXON; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LYSOSOME; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURAL HOMOLOGY; WESTERN BLOTTING;

EID: 84861668772     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1596/neo.111514     Document Type: Article

References (73)

1. Massague J and Pandiella A (1993). Membrane-anchored growth factors. Annu Rev Biochem 62, 515-541.
2. Fernandez-Larrea J, Merlos-Suarez A, Urena JM, Baselga J, and Arribas J (1999). A role for a PDZ protein in the early secretory pathway for the targeting of proTGF-α to the cell surface. Mol Cell 3, 423-433.
3. Kuo A, Zhong C, Lane WS, and Derynck R (2000). Transmembrane transforming growth factor-α tethers to the PDZ domain-containing, Golgi membrane associated protein p59/GRASP55. EMBO J 19, 6427-6439.
4. Franklin JL, Yoshiura K, Dempsey PJ, Bogatcheva G, Jeyakumar L, Meise KS, Pearsall RS, Threadgill D, and Coffey RJ (2005). Identification of MAGI-3 as a transforming growth factor-α tail binding protein. Exp Cell Res 303, 457-470.
5. Li C, Franklin JL, Graves-Deal R, Jerome WG, Cao Z, and Coffey RJ (2004). Myristoylated Naked2 escorts transforming growth factor α to the basolateral plasma membrane of polarized epithelial cells. Proc Natl Acad Sci USA 101, 5571-5576.
6. Dempsey PJ and Coffey RJ (1994). Basolateral targeting and efficient consumption of transforming growth factor-α when expressed in Madin-Darby canine kidney cells. J Biol Chem 269, 16878-16889.
7. Dempsey PJ, Meise KS, and Coffey RJ (2003). Basolateral sorting of transforming growth factor-α precursor in polarized epithelial cells: characterization of cytoplasmic domain determinants. Exp Cell Res 285, 159-174.
8. Brown CL, Coffey RJ, and Dempsey PJ (2001). The proamphiregulin cytoplasmic domain is required for basolateral sorting, but is not essential for constitutive or stimulus-induced processing in polarized Madin-Darby canine kidney cells. J Biol Chem 276, 29538-29549.
9. Bao J, Wolpowitz D, Role LW, and Talmage DA (2003). Back signaling by the Nrg-1 intracellular domain. J Cell Biol 161, 1133-1141.
10. Bao J, Lin H, Ouyang Y, Lei D, Osman A, Kim TW, Mei L, Dai P, Ohlemiller KK, and Ambron RT (2004). Activity-dependent transcription regulation of PSD-95 by neuregulin-1 and Eos. Nat Neurosci 7, 1250-1258.
11. Wang JY, Frenzel KE, Wen D, and Falls DL (1998). Transmembrane neuregulins interact with LIM kinase 1, a cytoplasmic protein kinase implicated in development of visuospatial cognition. J Biol Chem 273, 20525-20534.
12. Lin J, Hutchinson L, Gaston SM, Raab G, and Freeman MR (2001). BAG-1 is a novel cytoplasmic binding partner of the membrane form of heparin-binding EGF-like growth factor: a unique role for proHB-EGF in cell survival regulation. J Biol Chem 276, 30127-30132.
13. Hieda M, Isokane M, Koizumi M, Higashi C, Tachibana T, Shudou M, Taguchi T, Hieda Y, and Higashiyama S (2008). Membrane-anchored growth factor, HB-EGF, on the cell surface targeted to the inner nuclear membrane. J Cell Biol 180, 763-769.
14. Kinugasa Y, Hieda M, Hori M, and Higashiyama S (2007). The carboxylterminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol Chem 282, 14797-14806.
15. Nanba D and Higashiyama S (2004). Dual intracellular signaling by proteolytic cleavage of membrane-anchored heparin-binding EGF-like growth factor. Cytokine Growth Factor Rev 15, 13-19.
16. Adam RM, Danciu T, McLellan DL, Borer JG, Lin J, Zurakowski D, Weinstein MH, Rajjayabun PH, Mellon JK, and Freeman MR (2003). A nuclear form of the heparin-binding epidermal growth factor-like growth factor precursor is a feature of aggressive transitional cell carcinoma. Cancer Res 63, 484-490.
17. Stoeck A, Shang L, and Dempsey PJ (2010). Sequential and gamma-secretasedependent processing of the betacellulin precursor generates a palmitoylated intracellular-domain fragment that inhibits cell growth. J Cell Sci 123, 2319-2331.
18. Groenestege WM, Thebault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, van den Heuvel LP, van Cutsem E, Hoenderop JG, Knoers NV, et al. (2007). Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 117, 2260-2267.
19. Klonisch T, Glogowska A, Gratao AA, Grzech M, Nistor A, Torchia M, Weber E, de Angelis MH, Rathkolb B, Cuong HV, et al. (2009). The C-terminal cytoplasmic domain of human proEGF is a negative modulator of body and organ weights in transgenic mice. FEBS Lett 583, 1349-1357.
20. Pyka J, Glogowska A, Dralle H, Hoang-Vu C, and Klonisch T (2005). Cytoplasmic domain of proEGF affects distribution and post-translational modification of microtubuli and increases microtubule-associated proteins 1b and 2 production in human thyroid carcinoma cells. Cancer Res 65, 1343-1351.
21. Glogowska A, Pyka J, Kehlen A, Los M, Perumal P, Weber E, Cheng SY, Hoang-Vu C, and Klonisch T (2008). The cytoplasmic domain of proEGF negatively regulates motility and elastinolytic activity in thyroid carcinoma cells. Neoplasia 10, 1120-1130.
22. Waterman H, Katz M, Rubin C, Shtiegman K, Lavi S, Elson A, Jovin T, and Yarden Y (2002). A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 21, 303-313.
23. Johannessen LE, Pedersen NM, Pedersen KW, Madshus IH, and Stang E (2006). Activation of the epidermal growth factor (EGF) receptor induces formation of EGF receptorand Grb2-containing clathrin-coated pits. Mol Cell Biol 26, 389-401.
24. Yarden Y and Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137.
25. Mort JS and Buttle DJ (1997). Cathepsin B. Int J Biochem Cell Biol 29, 715-720.
26. Authier F, Metioui M, Bell AW, and Mort JS (1999). Negative regulation of epidermal growth factor signaling by selective proteolytic mechanisms in the endosome mediated by cathepsin B. J Biol Chem 274, 33723-33731.
27. Ohta T and Fukuda M (2004). Ubiquitin and breast cancer. Oncogene 23, 2079-2088.
28. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, and Carpenter G (1996). All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271, 5251-5257.
29. Wilkinson KD (2000). Ubiquitination and deubiquitination: targeting of proteins for degradation by the proteasome. Semin Cell Dev Biol 11, 141-148.
30. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, and Dikic I (2003). Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 5, 461-466.
31. Mizuno E, Iura T, Mukai A, Yoshimori T, Kitamura N, and Komada M (2005). Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes. Mol Biol Cell 16, 5163-5174.
32. Amerik AY and Hochstrasser M (2004). Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 1695, 189-207.
33. Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, Sato Y, Nishikawa K, Sun YJ, Sakurai M, et al. (2003). Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 12, 1945-1958.
34. Larsen CN, Krantz BA, and Wilkinson KD (1998). Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37, 3358-3368.
35. Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, and Jen J (1999). PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol 155, 711-715.
36. Dong J, Opresko LK, Chrisler W, Orr G, Quesenberry RD, Lauffenburger DA, and Wiley HS (2005). The membrane-anchoring domain of epidermal growth factor receptor ligands dictates their ability to operate in juxtacrine mode. Mol Biol Cell 16, 2984-2998.
37. Bell GI, Fong NM, Stempien MM, Wormsted MA, Caput D, Ku LL, Urdea MS, Rall LB, and Sanchez-Pescador R (1986). Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization. Nucleic Acids Res 14, 8427-8446.
38. Hu X, Bryington M, Fisher AB, Liang X, Zhang X, Cui D, Datta I, and Zuckerman KS (2002). Ubiquitin/proteasome-dependent degradation of Dtype cyclins is linked to tumor necrosis factor-induced cell cycle arrest. J Biol Chem 277, 16528-16537.
39. Waterman H, Levkowitz G, Alroy I, and Yarden Y (1999). The RING finger of c-Cbl mediates desensitization of the epidermal growth factor receptor. J Biol Chem 274, 22151-22154.
40. Rubin C, Gur G, and Yarden Y (2005). Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res 15, 66-71.
41. Stang E, Blystad FD, Kazazic M, Bertelsen V, Brodahl T, Raiborg C, Stenmark H, and Madshus IH (2004). Cbl-dependent ubiquitination is required for progression of EGF receptors into clathrin-coated pits. Mol Biol Cell 15, 3591-3604.
42. Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, Yarden Y, Weissman AM, and Lipkowitz S (2001). Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem 276, 27677-27684.
43. Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, Szollosi J, and Yarden Y (2003). Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem 278, 21323-21326.
44. Shih SC, Sloper-Mould KE, and Hicke L (2000). Monoubiquitin carries a novel internalization signal that is appended to activated receptors. EMBO J 19, 187-198.
45. Longva KE, Blystad FD, Stang E, Larsen AM, Johannessen LE, and Madshus IH (2002). Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 156, 843-854.
46. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover A, et al. (1999). Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4, 1029-1040.
47. Hicke L and Dunn R (2003). Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol 19, 141-172.
48. Alwan HA, van Zoelen EJ, and van Leeuwen JE (2003). Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem 278, 35781-35790.
49. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, and Tashiro Y (1991). Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 266, 17707-17712.
50. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, and Elliott PJ (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59, 2615-2622.
51. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, and Kikuchi H (1995). Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun 217, 1070-1077.
52. Hussain S, Foreman O, Perkins SL, Witzig TE, Miles RR, van Deursen J, and Galardy PJ (2010). The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia 24, 1641-1655.
53. Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, and Lee KJ (2009). Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 28, 117-127.
54. Mizukami H, Shirahata A, Goto T, Sakata M, Saito M, Ishibashi K, Kigawa G, Nemoto H, Sanada Y, and Hibi K (2008). PGP9.5 methylation as a marker for metastatic colorectal cancer. Anticancer Res 28, 2697-2700.
55. Bittencourt Rosas SL, Caballero OL, Dong SM, da Costa Carvalho Mda G, Sidransky D, and Jen J (2001). Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett 170, 73-79.
56. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, Carvalho AL, Jiang WW, Park HL, Kim MS, et al. (2005). PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 65, 4963-4968.
57. Yamashita K, Park HL, Kim MS, Osada M, Tokumaru Y, Inoue H, Mori M, and Sidransky D (2006). PGP9.5 methylation in diffuse-type gastric cancer. Cancer Res 66, 3921-3927.
58. Jang MJ, Baek SH, and Kim JH (2011). UCH-L1 promotes cancer metastasis in prostate cancer cells through EMT induction. Cancer Lett 302, 128-135.
59. Staub O and Rotin D (2006). Role of ubiquitylation in cellular membrane transport. Physiol Rev 86, 669-707.
60. Reyes-Turcu FE, Ventii KH, and Wilkinson KD (2009). Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 78, 363-397.
61. Kimura Y and Tanaka K (2010). Regulatory mechanisms involved in the control of ubiquitin homeostasis. J Biochem 147, 793-798.
62. Bifsha P, Landry K, Ashmarina L, Durand S, Seyrantepe V, Trudel S, Quiniou C, Chemtob S, Xu Y, Gravel RA, et al. (2007). Altered gene expression in cells from patients with lysosomal storage disorders suggests impairment of the ubiquitin pathway. Cell Death Differ 14, 511-523.
63. Komada M (2008). Controlling receptor downregulation by ubiquitination and deubiquitination. Curr Drug Discov Technol 5, 78-84.
64. de Melker AA, van der Horst G, and Borst J (2004). c-Cbl directs EGF receptors into an endocytic pathway that involves the ubiquitin-interacting motif of Eps15. J Cell Sci 117, 5001-5012.
65. Austin CD, De Maziere AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, and Scheller RH (2004). Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15, 5268-5282.
66. Abella JV and Park M (2009). Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endocrinol Metab 296, E973-E984.
67. Roepstorff K, Grovdal L, Grandal M, Lerdrup M, and van Deurs B (2008). Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer. Histochem Cell Biol 129, 563-578.
68. Zhou P, Fernandes N, Dodge IL, Reddi AL, Rao N, Safran H, DiPetrillo TA, Wazer DE, Band V, and Band H (2003). ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 278, 13829-13837.
69. Klapper LN, Waterman H, Sela M, and Yarden Y (2000). Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60, 3384-3388.
70. Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, Ortega-Cava C, Lakku-Reddi A, Naramura M, Band V, et al. (2008). A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 7, 1630-1640.
71. Sorkin A and Goh LK (2008). Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 314, 3093-3106.
72. Liu H, Buus R, Clague MJ, and Urbe S (2009). Regulation of ErbB2 receptor status by the proteasomal DUB POH1. PLoS One 4, e5544.
73. Niendorf S, Oksche A, Kisser A, Lohler J, Prinz M, Schorle H, Feller S, Lewitzky M, Horak I, and Knobeloch KP (2007). Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. Mol Cell Biol 27, 5029-5039.